Market Place
Sourcing Support
Billev`s Lutetium Chloride Lu-177 Receives Approval in Europe
08 Dec 2022 //
EMA
Billev`s Illuzyce (lutetium (177lu) chloride) Receives Approval in Europe
21 Sep 2022 //
EMA
MTTI and Monrol sign supply agreement for the clinical material Lu-177 nca
26 Nov 2021 //
WORLD-TODAY-NEWS
FDA reverses course, decides not to add suffixes to older biologics’
09 Mar 2019 //
ENDPTS
Y-mAbs preps $92M IPO to push lead assets through regulatory filing
28 Aug 2018 //
FIERCE BIOTECH
Endocyte & ITM Announce Long-Term Supply Agreement No-Carrier-Added Lutetium-177
09 Jul 2018 //
PRESS RELEASE
Endocyte Announces Pricing of Public Offering of Common Stock
28 Feb 2018 //
PRESS RELEASE
Endocyte & ITM Announce Supply Agreement for No-Carrier-Added Lutetium
26 Feb 2018 //
GLOBENEWSWIRE
US clears new option for gastroenteropancreatic tumours
29 Jan 2018 //
PHARMA TIMES
Novartis scores a quick FDA OK for its new cancer drug Lutathera, $4B buyout
27 Jan 2018 //
ENDPTS
Advanced Accelerator Gets Action Date for Lutathera from FDA
29 Aug 2017 //
NASDAQ
Telix and Atlab Conclude Therapeutic Product Development Agreement
18 Jan 2017 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.